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tion, the inflammation improved and even resolved after a 
3-month treatment course. The data indicate the essential 
role of the mucus PC content for protection against inflam-
mation in colon.  Copyright © 2012 S. Karger AG, Basel 
 State of the Art 
 Ulcerative colitis (UC) is a common chronic inflam-
matory disease in adults and children. It is defined as a 
diffuse inflammatory condition of the colonic mucosa 
that starts in the rectum and might extend to the cecum, 
causing erosion, ulceration and fibrotic repair. Manifes-
tations are pancolitis (approx. 20%), right-sided colitis 
(approx. 5%), left-sided colitis (approx. 30%), proctosig-
moiditis (approx. 20%) and proctitis (approx. 25%). The 
most typical symptoms are bloody diarrhea and pain 
during bowel movements.
 The etiology of UC is unknown. Based on epidemio-
logical examinations, it is surmised that along with a ge-
netic disposition environmental factors trigger the dis-
ease. A disturbed mucosal barrier is thought to be an ini-
tiating factor of the disease and subsequent attacks from 
the colonic commensal bacterial flora result in inflam-
mation of the mucosa  [1–3] .
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 Abstract 
 The colonic mucus serves a first barrier towards invasion of 
commensal bacteria in stools to prevent inflammation. One 
essential component of intestinal mucus is phosphatidyl-
choline (PC) which represents more than 90% of the phos-
pholipids in mucus indicative for a selective transport of PC 
into this compartment. It is arranged in lamellar structures as 
surfactant-like particles which provide a hydrophobic sur-
face on top of the hydrated mucus gel to prevent the inva-
sion of bacteria from intestinal lumen. In ulcerative colitis 
(UC), the mucus PC content is reduced by 70%, irrespective 
of the state of inflammation. Thus, it could represent an in-
trinsic primary pathogenetic condition predisposing to bac-
terial invasion and the precipitation of inflammation. Since 
PC was shown to be mainly secreted by the ileal mucosa 
from where it is assumed to move distally to the colon, the 
PC content along the colonic wall towards the rectum grad-
ually thins, with the least PC content in the rectum. This ex-
plains the start of the clinical manifestation of UC in the rec-
tum and the expansion from there to the upper parts of the 
colon. In three clinical trials, when missing mucus PC in UC 
was supplemented by an oral, delayed release PC prepara-
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 The Mucosal Barrier 
 The major physiological functions of the colon are the 
absorption of water and minerals, and the formation and 
discharge of feces containing mainly bacteria and nonab-
sorbable fibers. Concentrations of up to one trillion mi-
crobes per gram of stool are present in the colon and the 
distribution among the different bacterial species re-
mains astonishingly constant in each individual over 
long periods of time  [4] . Despite this enormous concen-
tration of commensal microbes, the mucosa remains in-
tact, and inflammation, erosions or ulcerations are not 
observed under physiological conditions. This is due to 
the nature of the mucosal barrier. Defensive mechanisms 
prohibit the invasion of bacteria and the mucosa-associ-
ated immune system remains quiescent. When bacteria 
invade the mucosa, the immune system is rapidly acti-
vated to prevent (as a last bid) systemic translocation and 
sepsis. This activation is associated with an inflamma-
tory response and apoptotic reactions (collateral damage) 
to defend against further invasion of bacteria. The muco-
sal barrier consists of the densely packed mucosal cell lay-
er connected by tight junctions. The most important 
component of the barrier, however, is the mucus layer as 
the first line of defense. Within this compartment, a high 
concentration of defensins is present; these are actively 
secreted into the mucus  [5] . They are small proteins which 
are highly conserved within the phylogenetic tree, and 
are responsible for eliminating invading bacteria by 
punching holes in the bacterial membranes in order to 
destroy them  [6] .
 The structural constitution of the mucus is essential 
for the barrier function. It is organized as a hydrated 
polymeric gel with a thickness of up to 830   m in the co-
lon  [7] . It is maintained by a network composed of the 
glycoprotein family of mucins (e.g. MUC 2) which are 
strongly negatively charged  [8, 9] . Although only little is 
known about the regulation and spacial distribution of 
the mucus scaffold components, it is evident that there 
are two layers with different properties and functions 
 [10] . The lower layer (50   m) is densely packed, devoid of 
bacteria and firmly attached to the epithelium. The upper 
layer is easily removable and contains mucins, cell debris 
and bacteria and may represent a turnover ‘garbage’ com-
partment for the lower, highly organized layer before it is 
lost to the lumen  [11] .
 Most internal surfaces of the organism consist of mu-
cosal membranes which produce mucus with high con-
centrations of phosphatidylcholine (PC)  [12–14] . These 
phospholipids are arranged in lamellar structures associ-
ated with specific proteins. In the lung, these lamellar 
bodies constitute the ‘surfactant’ and it has long been ig-
nored that such ‘surfactant-like particles’ are also present 
in the intestinal mucus  [15] . While the surfactant of the 
lung is known to play a role in gas exchange, surfactant-
like particles in the colon could – in addition to a possible 
role in substrate absorption – be useful, particularly to 
protect against the invasion of bacteria  [14, 15] . PC has 
amphiphilic characteristics with a positively charged po-
lar headgroup (phosphorylcholine) and a nonpolar hy-
drocarbon (fatty acid) tail. As the mucin network is 
strongly negatively charged, the PC head-group is be-
lieved to be electrostatically bound to the mucin network 
forming a monolayer with the fatty acid chains extending 
luminally  [16] . This establishes a hydrophobic surface on 
top of a hydrated gel which prevents the adherence and 
penetration of bacteria, i.e. it repels luminal content by 
acting like a closing seal  [17, 18] .
 Evidence for Impaired Mucus Phosphatidylcholine 
Secretion in Ulcerative Colitis 
 The fact that within the fraction of phospholipids in 
mucus  1 90% represent PC or lysophosphatidylcholine 
indicates that there is a selective transport process for PC 
into this compartment. When radiolabeled PC was in-
jected into the tail veins of rats, it was detected in the bile 
(as expected) and to a similar extent in the small intestine 
and to a (significantly) lesser degree in the colon  [19] 
( fig. 1 ).
 The question remains whether a low PC abundance in 
the colon represents the reduced PC secretion capacity of 
the colonic mucosa itself or is just a consequence of the 
minor mucosal surface area compared to the ileum. The 
mechanism involved in the luminal PC secretion across 
the intestinal wall is still unclear. First, it has to be deter-
mined whether PC is synthesized by the mucosal cells or 
whether it is recruited from blood, for instance, from li-
poproteins. The next question is whether PC is secreted 
by mucosal cells or traverses the mucosal barrier by pass-
ing through the tight junctions, as suggested by Alpers et 
al.  [20, 21] .
 The above-mentioned intestinal PC recovery studies 
(injection of radiolabeled PC into the tail veins of rats) 
indicate that it may be the intact PC which is translo-
cated into the mucus  [19] . It was noted that the PC trans-
location was stimulated by the presence of taurocholate 
in the perfusion medium. This suggests that the deter-
gent-like properties of bile acids stimulate the vectorial 
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transport into the intestinal lumen. It may indicate a yet 
unknown functional role of bile acids in the distal small 
intestine where adsorption of fatty acids is already com-
pleted and before bile acids are reabsorbed in the termi-
nal ileum.
 Low Phosphatidylcholine in Colonic Mucus as a
Key Pathogenetic Factor in Ulcerative Colitis 
 The finding is intriguing that PC is reduced by about 
70% in the mucus of the rectal mucosa of patients with 
UC, independent of the state of inflammation  [22] ( fig. 2 ).
 It has also been shown that in the terminal ileum and 
colon transversum, the mucus PC is markedly reduced 
compared to controls and patients with Crohn’s disease 
(CD)  [23] ( table 1 ).
 A lack of PC in the mucus has functional consequenc-
es. Below a certain threshold concentration of PC in mu-
cus, the hydrophobic barrier is broken and commensal 
bacteria can attack. As a surrogate marker of this impair-
ment, the surface tension of the mucus can be determined 
 [15] . In fact, it was shown that the surface tension of the 
mucus is significantly reduced in UC compared to CD 
and controls  [24] ( fig. 3 ).
 Hypothesis for Impaired Mucus Phosphatidylcholine 
Secretion in Ulcerative Colitis 
 The mechanisms involved in the reduced mucosal PC 
concentration have still to be elucidated. It may represent 
a multifactorial process, possibly involving the different 
steps of mucosal PC synthesis and/or intracellular traf-
ficking, cellular excretion and translocation/incorpora-
tion into the mucus (e.g. binding to the mucin network).
 Proper mucosal cell function requires attachment to 
the basal membrane as well as lateral adhesion via integ-
rin activation. The significance of the tight junction pro-
teins was recently highlighted by functional studies dem-
onstrating the kindlin protein family as essential part-
ners in the cell-basal membrane as well as cell-cell 
adhesion process  [25] . Indeed, deletion of the kindlin-1 
gene in mice resulted in a perinatally lethal UC pheno-
type  [26] . It could indicate a loss of mucosal cell function 
due to the detachment of mucosal cells from the basal 
membrane or the loss of adherence to each other. The 
most obvious explanation is that the mucosal cell layer is 
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 Fig. 1. Respective [ 3 H]-PC secretion rates 
in the jejunum, ileum, colon (fmol  ! h –1 
 ! cm intestine –1 ) and liver (fmol  ! h –1  ! 
g liver –1 ) of male rats in the presence of
2 m M TC. [ 3 H]-PC was injected intrave-
nously at time point 0. After 30 min, the 
secretion rates of each of the intestinal seg-
ments reached equilibrium and were sig-
nificantly different from one another. 
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 Fig. 2. Concentration of representative PC and LPC species in rec-
tal mucus obtained from controls and from CD and UC patients 
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disrupted and, thus, the commensal bacteria in stools can 
easily penetrate and induce inflammation. An alternative 
more speculative hypothesis is based on the suggestion of 
Alpers et al.  [20]  and Engle et al. [21] , that PC could selec-
tively traverse the tight junctional barrier for enrichment 
in the mucus layer. Thus, a disturbed tight junctional ar-
rangement could impair mucosal PC permeability result-
ing in a low mucus PC content. Those processes are at 
present being evaluated in our laboratory.
 Low Mucus Phosphatidylcholine and the Clinical 
Manifestation of Ulcerative Colitis 
 Irrespective of the underlying mechanism, it can be 
proposed that a lack of PC in mucus is a specific patho-
genetic feature of UC  [27–29] . It is the inherent low mucus 
PC content of as little as 30% compared to controls and 
patients with CD which impairs the mucosal barrier in 
UC. The finding that mucus PC is low irrespective of the 
inflammatory activity  [22] indicates that it represents an 
intrinsic primary defect which precipitates inflammation 
under certain conditions. The low mucus PC content may 
Table 1. T otal concentrations and molecular species composition of PC, LPC and sphingomyelin in colonic mucus from controls and 
from CD and UC patients
a    Source of PC
PC 32:0
(734 Da)
PC 34:2
(758 Da)
PC 34:1
(760 Da)
PC 36:4
(782 Da)
PC 36:3
(784 Da)
PC 36:2
(786 Da)
PC 36:1
(788 Da)
PC 38:4
(810 Da)
Total PC
pmol/100 
g protein
Con 5.280.6 18.580.9 28.580.7 7.980.7 9.981.1 15.480.6 9.980.5 4.780.3 2,7908354
CD 5.581.1 17.281.4 30.781.3 8.181.4 9.580.7 15.682.8 9.480.5 4.080.5 2,4508431
UC 13.381.8 13.181.0 27.781.4 6.481.0 8.381.1 12.981.1 14.581.6 3.880.8 7458148
vs. Con*** vs. Con*** vs. Con** vs. Con** vs. Con*** vs. Con***
vs. CD*** vs. CD*** vs. CD*** vs. CD***
b    Source of LPC or SM
LPC 16:0
(496 Da)
LPC 18:1
(522 Da)
LPC 18:2
(524 Da)
Total LPC
pmol/100 g 
protein
SM 16:0
(703 Da)
SM 24:2
(811 Da)
SM 24:1
(813 Da)
SM 24:0
(815 Da)
Total SM
pmol/100 g 
protein
Con 62.581.9 15.681.2 21.981.6 4,2378606 47.382.7 19.182.4 17.681.8 16.082.0 315839
CD 61.283.1 16.682.8 22.281.4 2,6758346 43.883.0 16.981.5 21.682.6 17.781.6 395871
UC 60.583.0 17.182.4 22.481.9 1,5728333 52.383.8 12.381.8 19.881.9 15.682.1 411863
vs. Con***
vs. CD**
Con = Controls; SM = sphingomyelin. ** p < 0.01, *** p < 0.001.
UC CON
0
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p < 0.0001
p < 0.0001
 Fig. 3. Colonic luminal surface hydrophobicity of 19 patients with 
UC, 10 with CD and 20 control subjects (CON) was compared. 
Patients with UC had a significantly lower surface hydrophobic-
ity (contact angle) than CD patients and controls, between whom 
no significant difference was detected. Overall: p = 0.0002, UC vs. 
CD: p  ! 0.05, UC vs. CON: p  ! 0.05. Data are expressed as me-
dian and IQR  [24] . 
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be sufficient to maintain a labile intact barrier function 
in asymptomatic patients with UC. Yet unknown factors 
may further reduce the mucus PC concentration below a 
critical threshold where the mucosal barrier is broken, 
followed by precipitation of an inflammatory episode. 
Under discussion are the hormonal changes or addition-
al environmental factors such as viral infections or, in 
particular, changes of the commensal flora towards 
strains with high phospholipase activities which further 
reduce the available protective PC within the mucus. On 
the other hand, colonization with low phospholipase ac-
tive strains, e.g.  Escherichia coli Nissle, may protect from 
the critical breakdown of the PC barrier.
 As bile acids in the distal small intestine could pro-
mote the PC secretory activity, it is conceivable that a low 
bile acid concentration in cholestatic disorders, e.g. pri-
mary sclerosing cholangitis, impairs the PC secretion 
and contributes to the manifestation of UC.
 The fact that PC secretion occurs mainly in the small 
intestine, particularly in the distal ileum and less in the 
colon  [19] , may predispose to the observed exclusive co-
lonic manifestation of UC. Thus, we originally proposed 
that the PC layer thins towards the rectum. This could be 
explained by the hypothesis that the mucus moves from 
the ileum to the rectum and that by exposure to phospho-
lipases of the commensal flora, the rectum represents the 
‘last lawn’ of PC content in mucus. The movement of mu-
cus concerns mainly the upper loosely attached layer. On 
the other hand, it would also be plausible that due to a 
higher concentration of bacteria in more consolidated 
stools and a longer time of exposure in the rectum, bacte-
rial phospholipases exert more activity. This would ex-
plain the start of inflammation in the rectum and the 
expansion from there to upper parts of the colon. The 
theory of downward-moving mucus is in line with the 
hypothesis that the lower the PC content in the mucus, 
the greater the extent of the disease with the least PC con-
tent in pancolitis. A primary low PC secretion capacity in 
the small intestine as a key pathogenetic feature in UC 
could also explain the phenomenon of pouchitis in the 
ileoanal pouch after colectomy for UC. Indeed, pouchitis 
after colectomy for UC is observed in up to 70% of cases. 
However, in most instances, it is a mild to moderate in-
flammation and only in around 10% does severe pouchi-
tis occur. In contrast, the ileoanal pouch after colectomy 
for familial adenomatous polyposis almost never leads to 
pouchitis. We propose that the PC secretory capacity is 
significantly reduced in UC pouch mucosa compared to 
in familial adenomatous polyposis. This fits with the no-
tion that the PC mucus barrier is impaired and the com-
mensal stool flora within the pouch precipitates the in-
flammation. The same mechanism of action may apply 
to the phenomenon of diversion colitis where the PC con-
taining ileal mucus is excluded from entry into the colon.
 Proving the Concept in Clinical Trials 
 According to the concept that the lack of PC contrib-
utes to the pathogenesis of UC, we proposed that the local 
substitution of PC could enhance or even normalize the 
mucus PC content and reestablish the mucosal barrier. It 
is suggested that the application of high concentrations of 
PC in the lumen may facilitate its integration into the mu-
cus. It may first distribute within the upper mucus layer 
from where it may be integrated into the lower, densely 
packed mucus layer to reconstitute the lamellar PC mono-
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 Fig. 4. Changes in the CAI score from baseline to the end of the 
study. Changes at different doses of delayed intestinal release PC 
(rPC) are presented as box- and-whisker plots [25th percentile 
(lower horizontal line), median (middle horizontal line), 75th per-
centile (upper horizontal line) and extreme values ( X )]. A signifi-
cant improvement was registered at 1 g of rPC compared to the 
lowest dose of 0.5 g rPC, with no further differences registered 
concerning all following doses. The improvements in the CAI 
score from baseline to the end of the study were 2.5 (IQR 2.0–3.0) 
in the 0.5-gram dose arm, 7.0 (1.0–7.0) in the 1-gram dose arm, 
5.5 (4.0–7.0) and 6 (4.0–9.0) in the 4-gram dose arm  [35] .  X = Ex-
treme value, * = outliers. 
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layer for the enhancement of the hydrophobic protective 
barrier against luminal bacteria. An additional aspect of 
PC supplementation relates to the anti-inflammatory 
properties of PC  [30, 31] . It may partition into the muco-
sal cell plasma membrane as such or is taken up after 
cleavage to LPC and fatty acids.
 PC was shown to decrease TNF-  secretion with con-
sequent NF-  B deactivation. The mechanism of action of 
PC is not entirely clear, but there is evidence that via PC, 
the p65 subunit can interact with F-actin and, thus, pre-
vent NF-  B activation  [32, 33] .
 For the purpose of colonic delivery of missing PC, a 
delayed release oral formulation was developed  [34] . En-
capsulation with Eudragit S100 established a pH-depen-
dent release in the distal ileum. It was indeed shown that 
the colonic mucus PC content increased to normal values 
 [34] .
 The concept of local supplementation of missing PC in 
the colonic mucus was evaluated in a first clinical trial in 
patients with chronic active UC [clinical activity index 
(CAI)  6 4], but without concomitant steroid treatment 
 [34] . In a double-blind, randomized, placebo-controlled 
study, 60 patients were treated for 3 months with delayed-
release PC (rPC) or placebo (4  ! 0.5 g daily). Ninety per-
cent of the rPC-treated patients reached clinical remis-
sion (CAI  ^  3; 16 patients) or showed a  6 50% improve-
ment of their clinical activity (median reduction of the 
CAI by 7 score points) versus 10% in the placebo group. 
This was accompanied by a  6 50% improvement of the 
endoscopic activity index (EAI) in 11 patients (median 
improvement of the EAI by 3 score points) compared to 
no change in the placebo group. The same was true for 
improvement of histology which was only observed in the 
rPC group. The initial median histology score of 3 (IQR 
2–4) decreased to 2 (1–2) (p  ! 0.0001). In parallel, the 
quality of life improved by 50% in 16 of 29 evaluated rPC-
treated patients versus 2 of 28 patients in the placebo 
group.
 In a dose-finding study with chronic active pancolitis 
patients, CAI improvement started with 1 g of rPC daily 
reaching a plateau at 3 g and 4 g rPC daily  [35] ( fig. 4 ). 
This was paralleled by improvement of the EAI. The me-
dian time to clinical response was 5 (IQR 2–8) weeks. 
Mild bloating was registered in 40% of patients with no 
difference between the study groups. Three of 10 patients 
in the 4-gram dose group reported nausea. Other adverse 
events were not registered.
 Even more convincing proof of its clinical efficacy 
was obtained when the patient population of steroid-re-
fractory UC that was the most difficult to treat was eval-
uated  [36] . At a daily dose of 2 g of rPC for 3 months, 
50% of the patients could be withdrawn from steroids 
and at the same time achieved clinical remission (CAI 
 ^  3) or a  6 50% CAI improvement compared to 10% in 
the placebo-treated group. In total, 80% of the rPC-
treated patients could discontinue the steroid therapy. 
In parallel with the clinical improvement, 60% of rPC 
patients fell below an EAI of 4 and 70% had an improved 
EAI of  6 50% compared to only 3% of the placebo re-
cipients.
 Conclusion 
 Thus, a new concept for the therapy of UC has been 
developed based on the observation that a lack of PC in 
colonic mucus is of key pathogenetic relevance. It is the 
logical consequence that insufficient PC content would 
require substitution to maintain the mucosal barrier. 
Only a delayed-release oral PC preparation is able to de-
liver PC to the distal ileum. Solubilization with bile acids 
and incorporation of PC into the mucus enables the rees-
tablishment of a hydrophobic first line of defense. 
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